



Q1 2023 Financial Results

Appendix



Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended	
	March 31, 2023	March 31, 2022
Reconciliation of GAAP to Non-GAAP research and development:		
GAAP research and development	\$ 230,569	\$ 169,893
Less: Stock-based compensation expenses	(16,232)	(11,617)
Non-GAAP research and development	<u>\$ 214,337</u>	<u>\$ 158,276</u>
Reconciliation of GAAP to Non-GAAP selling, general and administrative:		
GAAP selling, general and administrative	\$ 183,659	\$ 154,471
Less: Stock-based compensation expenses	(23,715)	(17,676)
Non-GAAP selling, general and administrative	<u>\$ 159,944</u>	<u>\$ 136,795</u>
Reconciliation of GAAP to Non-GAAP operating loss:		
GAAP operating loss	\$ (149,807)	\$ (146,732)
Add: Stock-based compensation expenses	39,947	29,293
Non-GAAP operating loss	<u>\$ (109,860)</u>	<u>\$ (117,439)</u>



Anylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Growth at Constant Currency

	Three Months Ended March 31, 2023
Total TTR net product revenue growth, as reported	49 %
Add: Impact of foreign currency translation	5
Total TTR net product revenue growth at constant currency	<u>54 %</u>
GIVLAARI net product revenue growth, as reported	36 %
Add: Impact of foreign currency translation	3
GIVLAARI net product revenue growth at constant currency	<u>39 %</u>
OXLUMO net product revenue growth, as reported	66 %
Add: Impact of foreign currency translation	4
OXLUMO net product revenue growth at constant currency	<u>70 %</u>
Total net product revenue growth, as reported	48 %
Add: Impact of foreign currency translation	4
Total net product revenue growth at constant currency	<u>52 %</u>
Total revenue growth, as reported	50 %
Add: Impact of foreign currency translation	3
Total revenue growth at constant currency	<u>53 %</u>